CORT
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Corcept announced a positive CHMP opinion recommending EU marketing authorization for Lifyorli (relacorilant)Sep 18, 2026
- Corcept resubmitted its NDA for relacorilant as a treatment for Cushing's syndromeJun 18, 2026
- FDA approved Corcept’s relacorilant combination for platinum-resistant ovarian cancerMar 26, 2026
- Corcept receives complete response letter for relacorilant in hypercortisolism treatmentDec 31, 2025
- Corcept to present new late-breaking data from pivotal ROSELLA trial of Relacorilant in platinum-resistant ovarian cancer at ESMO 2025Sep 23, 2025